Fresenius (company)

mAbxience Appoints Jurgen Van Broeck as New CEO

Retrieved on: 
木曜日, 5月 9, 2024
CDMO, Quality of life, Merck, Fresenius (company), Pharmaceutical industry

MADRID, May 9, 2024 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer.

Key Points: 
  • MADRID, May 9, 2024 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer.
  • Under his leadership, mAbxience has successfully enhanced its global presence and continued to excel in delivering accessible, high-quality medicines worldwide.
  • Jurgen joined mAbxience with nearly two decades of extensive experience in the healthcare sector, including significant roles at multinational corporations such as Merck and Mundipharma.
  • mAbxience remains committed to its mission of enhancing the quality of life through universal access to high-quality biopharmaceuticals.

mAbxience Appoints Jurgen Van Broeck as New CEO

Retrieved on: 
木曜日, 5月 9, 2024
CDMO, Quality of life, Merck, Fresenius (company), Pharmaceutical industry

MADRID, May 9, 2024 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer.

Key Points: 
  • MADRID, May 9, 2024 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer.
  • Prior to his new role, Jurgen has been at the forefront of mAbxience's strategic initiatives, overseeing all commercial, business development and market access activities.
  • Under his leadership, mAbxience has successfully enhanced its global presence and continued to excel in delivering accessible, high-quality medicines worldwide.
  • Jurgen joined mAbxience with nearly two decades of extensive experience in the healthcare sector, including significant roles at multinational corporations such as Merck and Mundipharma.

EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024

Retrieved on: 
金曜日, 5月 10, 2024
FDA, Internet, CFO, Investment, PIN, Fresenius (company), Food, Biosimilar, Pembrolizumab, Depreciation, Johnson & Johnson, Teva, Partnership, Eye, Tax, Ustekinumab, Gulf Cooperation Council, MENA, GCC, Scott Richter, Patient, Acquisition, EMA, Marketing, Novartis, European Medicines Agency, Pharmaceutical industry

Press Release // May 8, 2024

Key Points: 
  • Press Release // May 8, 2024
    Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) today published figures for the first quarter of financial year 2024.
  • Formycon confirms the financial guidance issued in April for the 2024 financial year.
  • FYB201 is expected to be marketed under the trade name Ravegza® [2] in Saudi Arabia from the second quarter of 2024.
  • The Management Board of Formycon AG will discuss the development of the company and the key financial figures for the first quarter of the financial year 2024 in a conference call.

EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance

Retrieved on: 
金曜日, 5月 3, 2024
FDA, CFO, Patient, Bank statement, Internet, Web browser, Investment, Zoom, Fresenius (company), Biosimilar, Pembrolizumab, Depreciation, Annual report, Partnership, WACC, Ustekinumab, Development, Tax, EMA, Ranibizumab, Economic development, Marketing, ID, Telephone, COVID-19, Growth, Cryptocurrency

In 2023, we reached all the operational milestones we had set and therewith laid the foundations for a successful and profitable future.

Key Points: 
  • In 2023, we reached all the operational milestones we had set and therewith laid the foundations for a successful and profitable future.
  • Enno Spillner, CFO of Formycon AG, adds: “We have presented excellent financial figures for 2023 and reached or exceeded the guidance.
  • In future reporting, Formycon will replace the previous financial performance indicator "consolidated net result" with the new indicator "adjusted Group EBITDA".
  • The complete Annual Report 2023 can be found on the Formycon website at Financial Reports.

EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast

Retrieved on: 
金曜日, 5月 3, 2024
CFO, KPI, Investment, Fresenius (company), Depreciation, Partnership, WACC, Tax, Ranibizumab, Marketing, Bank statement, Annual report, COVID-19, Growth, Cryptocurrency

conference call at 3:00 p.m. (CEST)

Key Points: 
  • conference call at 3:00 p.m. (CEST)
    Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, "Formycon") today announced preliminary, unaudited consolidated figures for the 2023 financial year and overall looks back on the past year very positively.
  • "We look back on a very successful financial year with significant progress in development projects and deliver strong preliminary financial figures for the Formycon Group.
  • Formycon will publish the final and audited figures for the 2023 financial year as well as the annual report on April 25, 2024.
  • During a conference call, the Management Board will discuss the performance of the company and key financial figures.

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

Retrieved on: 
月曜日, 4月 15, 2024
Medical Supplies, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Fresenius (company), Adalimumab, Pegfilgrastim, Biosimilar, Traction, Giant cell arteritis, Condylar resorption, Helios, Tocilizumab, Patient, Rheumatoid arthritis, Multimedia, Autoimmunity, Pharmaceutical industry

Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab).

Key Points: 
  • Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab).
  • (Photo: Business Wire)
    Michael Sen, CEO of Fresenius: “With the launch of Tyenne® in the U.S., we have reached another important milestone in accelerating our strong (Bio)Pharma momentum.
  • Tyenne® is Fresenius’ third approved biosimilar available in the U.S. and the second within its immunology portfolio.
  • Pierluigi Antonelli, CEO of Fresenius Kabi: “Tyenne® will impact the treatment landscape for inflammatory and immune diseases in the U.S.

GS1 Connect 2024 Agenda Offers Supply Chain Best Practices Across Retail, Grocery, Foodservice and Healthcare Industries

Retrieved on: 
水曜日, 4月 24, 2024
EON, Supply, Target, Rothy's, The Coca-Cola Company, RFID, McDonald's, Fresenius (company), PepsiCo, Exhibition, Avery Dennison, Cardinal Health, Johnson & Johnson, Conference, Artificial intelligence, McKesson Corporation, Automation, GS1, Sustainability, Procter & Gamble, Bitly, Food, Salsify, SPS Commerce, Commerce, GS1 US, Digital, General Mills, Health, Management

EWING, NJ., April 24, 2024 /PRNewswire/ -- GS1 Connect 2024, the conference and exhibition hosted by GS1 US, will feature more than 300 leading companies that will share strategies for leveraging GS1 Standards to enable end-to-end supply chain visibility. Among the companies participating are Avery Dennison, BD, Bitly, Cardinal Health, Chick-fil-A, Dillard's, Fresenius Kabi, General Mills, Johnson & Johnson, Mars, McCormick & Company, McDonald's, McKesson, PepsiCo., Pfizer, Procter & Gamble, Target, Wegmans and more. The event will be held June 4-6, 2024, at the Orlando World Center Marriott in Orlando, Florida. To view the agenda, visit www.gs1us.org/gs1connect.

Key Points: 
  • The event will be held June 4-6, 2024, at the Orlando World Center Marriott in Orlando, Florida.
  • "GS1 Connect offers an unrivaled opportunity for industry members to learn about new developments and strategies that are driving visibility and optimization for an increasingly connected technology-driven world."
  • GS1 Connect is sponsored by 1WorldSync, Antares Vision Group, Avery Dennison, The Coca-Cola Company, Data Council + RIVIR, LSPedia, OPTEL, Salsify, SATO, Share-ify, SPS Commerce, Syndigo, and Trustwell.
  • To learn more about GS1 Connect 2024, visit www.gs1us.org/gs1connect .

EQS-News: Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada

Retrieved on: 
水曜日, 4月 10, 2024
Ulcerative colitis, Psoriasis, Ustekinumab, Patient, EMA, Interleukin, European Medicines Agency, Fresenius (company), Cytokine, Johnson & Johnson, FDA, Food, Pharmaceutical industry

Press release // March 18, 2024

Key Points: 
  • Press release // March 18, 2024
    Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with Johnson & Johnson concerning the commercialization of FYB202, a biosimilar to Stelara®1 (ustekinumab), in Europe and Canada.
  • It was agreed to keep the terms of the agreement confidential.
  • Our aim is to make a significant difference in patients' lives by providing them with reliable, high-quality, and affordable treatment options.
  • In February 2023, Formycon and Fresenius Kabi had entered into a global license agreement for the ustekinumab biosimilar candidate FYB202, under which FYB202 will be marketed by Fresenius Kabi in key global markets following successful approval.

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Retrieved on: 
木曜日, 4月 4, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TEVA, Partnership, Business, Patient, CGMP, Good manufacturing practice, Business development, Doctor of Philosophy, Biosimilar, Fresenius (company), Teva, Generic drug

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.

Key Points: 
  • Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
  • Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in global oncology care.
  • The licensing agreement covers multiple global markets, including in Europe and the United States, signaling a major step in mAbxience’s global expansion strategy, and supports a key element of Teva’s Pivot to Growth strategy, announced in 2023, to expand its biosimilar pipeline through business development and strategic partnerships.
  • Under the terms of the licensing agreement, mAbxience will leverage its expertise in biosimilar development and its state-of-the-art, current Good Manufacturing Practice (cGMP)-approved facilities in Spain and Argentina, to develop and produce the biosimilar product.

Wind River Achieves Certification Under Prestigious Service Capability & Performance Standards

Retrieved on: 
火曜日, 3月 12, 2024
Telecommunications, Software, Networks, Internet, Hardware, Data Management, Technology, Security, Wind, SCP, Certification, Fresenius (company), SS&C Advent, McKesson Corporation, Management

Wind River® , a global leader in delivering software for mission-critical intelligent systems, has achieved certification under the prestigious Service Capability & Performance (SCP) Standards .

Key Points: 
  • Wind River® , a global leader in delivering software for mission-critical intelligent systems, has achieved certification under the prestigious Service Capability & Performance (SCP) Standards .
  • This certification recognizes the Wind River Technical Support organization for delivering top-quality service and support by meeting a stringent set of performance factors that represent best practices in the industry.
  • Wind River continually strives to find new ways to best support our customers’ increasingly complex needs, and our certification under the SCP Standards is a testament to that commitment.”
    The SCP Standards are designed to improve the quality and effectiveness of technology service operations.
  • “Wind River can be proud to be placed among industry-leading service providers through its attainment of certification under the SCP Standards.”
    Wind River joins the ranks of leading technology companies certified under the SCP Standards.